Musther Helen, Gill Katherine L, Chetty Manoranjenni, Rostami-Hodjegan Amin, Rowland Malcolm, Jamei Masoud
Simcyp Limited (a Certara Company), Blades Enterprise Centre, John Street, Sheffield, S2 4SU, UK,
AAPS J. 2015 Sep;17(5):1268-79. doi: 10.1208/s12248-015-9796-7. Epub 2015 Jun 23.
Physiologically based pharmacokinetic (PBPK) models can over-predict maximum plasma concentrations (C(max)) following intravenous administration. A proposed explanation is that invariably PBPK models report the concentration in the central venous compartment, rather than the site where the samples are drawn. The purpose of this study was to identify and validate potential corrective models based on anatomy and physiology governing the blood supply at the site of sampling and incorporate them into a PBPK platform. Four models were developed and scrutinised for their corrective potential. All assumed the peripheral sampling site concentration could be described by contributions from surrounding tissues and utilised tissue-specific concentration-time profiles reported from the full-PBPK model within the Simcyp Simulator. Predicted concentrations for the peripheral site were compared to the observed C(max). The models results were compared to clinical data for 15 studies over seven compounds (alprazolam, imipramine, metoprolol, midazolam, omeprazole, rosiglitazone and theophylline). The final model utilised tissue concentrations from adipose, skin, muscle and a contribution from artery. Predicted C(max) values considering the central venous compartment can over-predict the observed values up to 10-fold whereas the new sampling site predictions were within 2-fold of observed values. The model was particularly relevant for studies where traditional PBPK models over-predict early time point concentrations. A successful corrective model for C(max) prediction has been developed, subject to further validation. These models can be enrolled as built-up modules into PBPK platforms and potentially account for factors that may affect the initial mixing of the blood at the site of sampling.
基于生理的药代动力学(PBPK)模型可能会高估静脉给药后的最大血浆浓度(C(max))。一种提出的解释是,PBPK模型总是报告中心静脉隔室中的浓度,而不是采样部位的浓度。本研究的目的是识别并验证基于支配采样部位血液供应的解剖学和生理学的潜在校正模型,并将其纳入PBPK平台。开发了四个模型并对其校正潜力进行了审查。所有模型都假设外周采样部位的浓度可以通过周围组织的贡献来描述,并利用了Simcyp模拟器中全PBPK模型报告的组织特异性浓度-时间曲线。将外周部位的预测浓度与观察到的C(max)进行比较。将模型结果与七种化合物(阿普唑仑、丙咪嗪、美托洛尔、咪达唑仑、奥美拉唑、罗格列酮和茶碱)的15项研究的临床数据进行了比较。最终模型利用了脂肪、皮肤、肌肉的组织浓度以及动脉的贡献。考虑中心静脉隔室的预测C(max)值可能会高估观察值达10倍,而新的采样部位预测值在观察值的2倍以内。该模型对于传统PBPK模型高估早期时间点浓度的研究尤为相关。已开发出一种成功的用于C(max)预测的校正模型,有待进一步验证。这些模型可以作为构建模块纳入PBPK平台,并可能考虑到可能影响采样部位血液初始混合的因素。